OncoMatch

OncoMatch/Clinical Trials/NCT07249073

CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma

Is NCT07249073 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CAR19-BCMA dual-target CAR-T for multiple myeloma.

Early Phase 1RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07249073Data as of May 2026

Treatment: CAR19-BCMA dual-target CAR-T — 1. Objective to evaluate the safety and tolerability of CAR19-BCMA dual-target CAR-T in the treatment of relapsed / refractory multiple myeloma. 2. To determine the maximum tolerated dose (MTD) of car19-bcma dual target car-t in the treatment of relapsed / refractory multiple myeloma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Biomarker criteria

Required: BCMA overexpression (positive)

The expression of BCMA and / or CD19 in myeloma cells was positive confimed by flow cytometry or immunohistochemistry

Required: CD19 overexpression (positive)

The expression of BCMA and / or CD19 in myeloma cells was positive confimed by flow cytometry or immunohistochemistry

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: proteasome inhibitor

have received at least 1 line treatment (including proteasome inhibitors (PI), immunomodulatory drugs (IMID), CD38 mAb)

Must have received: immunomodulatory agent

have received at least 1 line treatment (including proteasome inhibitors (PI), immunomodulatory drugs (IMID), CD38 mAb)

Must have received: CD38 monoclonal antibody

have received at least 1 line treatment (including proteasome inhibitors (PI), immunomodulatory drugs (IMID), CD38 mAb)

Lab requirements

Blood counts

hgb ≥ 60g/l (transfusible)

Kidney function

creatinine ≤ 2 × uln

Liver function

total bilirubin ≤ 1.5 × uln; alt and ast ≤ 2.5 × uln

Cardiac function

left ventricular ejection fraction ≥ 50%; blood oxygen saturation >90%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify